The rule of five should not impede anti-parasitic drug development

The “rule of 5” has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for “double cutoffs” to preclude development of new drug leads for parasitic dis...

Descripción completa

Detalles Bibliográficos
Autores principales: McKerrow, James H., Lipinski, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Invited Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473536/
https://www.ncbi.nlm.nih.gov/pubmed/28623818
http://dx.doi.org/10.1016/j.ijpddr.2017.05.003
_version_ 1783244303026356224
author McKerrow, James H.
Lipinski, Christopher A.
author_facet McKerrow, James H.
Lipinski, Christopher A.
author_sort McKerrow, James H.
collection PubMed
description The “rule of 5” has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for “double cutoffs” to preclude development of new drug leads for parasitic diseases.
format Online
Article
Text
id pubmed-5473536
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-54735362017-06-26 The rule of five should not impede anti-parasitic drug development McKerrow, James H. Lipinski, Christopher A. Int J Parasitol Drugs Drug Resist Invited Article The “rule of 5” has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for “double cutoffs” to preclude development of new drug leads for parasitic diseases. Elsevier 2017-05-27 /pmc/articles/PMC5473536/ /pubmed/28623818 http://dx.doi.org/10.1016/j.ijpddr.2017.05.003 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Invited Article
McKerrow, James H.
Lipinski, Christopher A.
The rule of five should not impede anti-parasitic drug development
title The rule of five should not impede anti-parasitic drug development
title_full The rule of five should not impede anti-parasitic drug development
title_fullStr The rule of five should not impede anti-parasitic drug development
title_full_unstemmed The rule of five should not impede anti-parasitic drug development
title_short The rule of five should not impede anti-parasitic drug development
title_sort rule of five should not impede anti-parasitic drug development
topic Invited Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473536/
https://www.ncbi.nlm.nih.gov/pubmed/28623818
http://dx.doi.org/10.1016/j.ijpddr.2017.05.003
work_keys_str_mv AT mckerrowjamesh theruleoffiveshouldnotimpedeantiparasiticdrugdevelopment
AT lipinskichristophera theruleoffiveshouldnotimpedeantiparasiticdrugdevelopment
AT mckerrowjamesh ruleoffiveshouldnotimpedeantiparasiticdrugdevelopment
AT lipinskichristophera ruleoffiveshouldnotimpedeantiparasiticdrugdevelopment

Ejemplares similares